Depressive breakthrough

A. A. Nierenberg, Jonathan E. Alpert

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

Controlled studies of continuation and maintenance pharmacotherapy have consistently shown the advantage of drug therapy over placebo for the prevention of relapses and recurrences, particularly when antidepressant medications are maintained at the full dose required initially to establish remission. Nevertheless, controlled and observational studies indicate substantial rates of relapse and recurrence despite long-term treatment. Although depressive breakthrough is a common clinical problem, few uncontrolled studies and no controlled trials are available on management of depressive breakthrough. Three principal pharmacologic strategies seem to be (1) increasing dose, (2) adding another agent, and (3) switching antidepressants. Controlled studies of long-term treatment are needed to identify the optimal nature and sequence of approaches for re-emergent depression and to determine what symptom severity and duration should prompt the initiation of treatment.

Original languageEnglish (US)
Pages (from-to)731-742
Number of pages12
JournalPsychiatric Clinics of North America
Volume23
Issue number4
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Recurrence
Antidepressive Agents
Drug Therapy
Secondary Prevention
Observational Studies
Therapeutics
Placebos
Maintenance

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Depressive breakthrough. / Nierenberg, A. A.; Alpert, Jonathan E.

In: Psychiatric Clinics of North America, Vol. 23, No. 4, 2000, p. 731-742.

Research output: Contribution to journalReview article

Nierenberg, A. A. ; Alpert, Jonathan E. / Depressive breakthrough. In: Psychiatric Clinics of North America. 2000 ; Vol. 23, No. 4. pp. 731-742.
@article{1713c1cae0014da2afaa42d69e9da91b,
title = "Depressive breakthrough",
abstract = "Controlled studies of continuation and maintenance pharmacotherapy have consistently shown the advantage of drug therapy over placebo for the prevention of relapses and recurrences, particularly when antidepressant medications are maintained at the full dose required initially to establish remission. Nevertheless, controlled and observational studies indicate substantial rates of relapse and recurrence despite long-term treatment. Although depressive breakthrough is a common clinical problem, few uncontrolled studies and no controlled trials are available on management of depressive breakthrough. Three principal pharmacologic strategies seem to be (1) increasing dose, (2) adding another agent, and (3) switching antidepressants. Controlled studies of long-term treatment are needed to identify the optimal nature and sequence of approaches for re-emergent depression and to determine what symptom severity and duration should prompt the initiation of treatment.",
author = "Nierenberg, {A. A.} and Alpert, {Jonathan E.}",
year = "2000",
doi = "10.1016/S0193-953X(05)70194-5",
language = "English (US)",
volume = "23",
pages = "731--742",
journal = "Psychiatric Clinics of North America",
issn = "0193-953X",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Depressive breakthrough

AU - Nierenberg, A. A.

AU - Alpert, Jonathan E.

PY - 2000

Y1 - 2000

N2 - Controlled studies of continuation and maintenance pharmacotherapy have consistently shown the advantage of drug therapy over placebo for the prevention of relapses and recurrences, particularly when antidepressant medications are maintained at the full dose required initially to establish remission. Nevertheless, controlled and observational studies indicate substantial rates of relapse and recurrence despite long-term treatment. Although depressive breakthrough is a common clinical problem, few uncontrolled studies and no controlled trials are available on management of depressive breakthrough. Three principal pharmacologic strategies seem to be (1) increasing dose, (2) adding another agent, and (3) switching antidepressants. Controlled studies of long-term treatment are needed to identify the optimal nature and sequence of approaches for re-emergent depression and to determine what symptom severity and duration should prompt the initiation of treatment.

AB - Controlled studies of continuation and maintenance pharmacotherapy have consistently shown the advantage of drug therapy over placebo for the prevention of relapses and recurrences, particularly when antidepressant medications are maintained at the full dose required initially to establish remission. Nevertheless, controlled and observational studies indicate substantial rates of relapse and recurrence despite long-term treatment. Although depressive breakthrough is a common clinical problem, few uncontrolled studies and no controlled trials are available on management of depressive breakthrough. Three principal pharmacologic strategies seem to be (1) increasing dose, (2) adding another agent, and (3) switching antidepressants. Controlled studies of long-term treatment are needed to identify the optimal nature and sequence of approaches for re-emergent depression and to determine what symptom severity and duration should prompt the initiation of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0034522602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034522602&partnerID=8YFLogxK

U2 - 10.1016/S0193-953X(05)70194-5

DO - 10.1016/S0193-953X(05)70194-5

M3 - Review article

VL - 23

SP - 731

EP - 742

JO - Psychiatric Clinics of North America

JF - Psychiatric Clinics of North America

SN - 0193-953X

IS - 4

ER -